Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology,Transmembrane Potential,Fragmentation,Amyloidosis,and Neuronal Cell Death Found in Brains of Alzheimer’s Disease Patients
Restricted accessResearch articleFirst published online October 25, 2022
Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology,Transmembrane Potential,Fragmentation,Amyloidosis,and Neuronal Cell Death Found in Brains of Alzheimer’s Disease Patients
Alzheimer’s disease (AD) is a neurological disease that has both a genetic and non-genetic origin. Mitochondrial dysfunction is a critical component in the pathogenesis of AD as deficits in oxidative capacity and energy production have been reported.
Objective:
Nuclear-encoded mitochondrial genes were studied in order to understand the effects of mitochondrial expression changes on mitochondrial function in AD brains. These expression data were to be incorporated into a testable mathematical model for AD used to further assess the genes of interest as therapeutic targets for AD.
Methods:
RT2-PCR arrays were used to assess expression of 84 genes involved in mitochondrial biogenesis in AD brains. A subset of mitochondrial genes of interest was identified after extensive Ingenuity Pathway Analysis (IPA) (Qiagen). Further filtering of this subset of genes of interest was achieved by individual qPCR analyses. Expression values from this group of genes were included in a mathematical model being developed to identify potential therapeutic targets.
Results:
Nine genes involved in trafficking proteins to mitochondria, morphology of mitochondria, maintenance of mitochondrial transmembrane potential, fragmentation of mitochondria and mitochondrial dysfunction, amyloidosis, and neuronal cell death were identified as significant to the changes seen. These genes include TP53, SOD2, CDKN2A, MFN2, DNM1L, OPA1, FIS1, BNIP3, and GAPDH.
Conclusion:
Altered mitochondrial gene expression indicates that a subset of nuclear-encoded mitochondrial genes compromise multiple aspects of mitochondrial function in AD brains. A new mathematical modeling system may provide further insights into potential therapeutic targets.
Alzheimer’s Association (2022) Alzheimer’s disease facts and figures. Alzheimers Dement18, 700–789.
2.
GoateA, Chartier-HarlinM-C, MullanM, BrownJ, CrawfordF, FidaniL, GuiffraL, HaynesA, IrvingN, JamesL, MantR, NewtonP, RookeK, RoquesP, TalbotC, Pericak-VanceM, RosesA, WilliamsonR, RossorM, OwenM, HardyJ (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature349, 704–706.
3.
SuzukiN, CheungTT, CaiXD, OdakaA, OtvosL, EckmanC, GoldeTE, YounkinSG (1994) An increased percentage of long amyloid β-protein secreted by familial amyloid β-protein precursor (β-APP717) mutants. Science264, 1336–1340.
4.
EckmanCB, MehtaND, CrookR, Perez-turJ, PriharG, PfeifferE, Graff-RadfordN, HinderP, YagerD, ZenkB, RefoloLM, PradaCM, YounkinSG, HuttonM, HardyJ (1997) A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of Aβ42(43). Hum Mol Genet6, 2087–2089.
5.
MurrelJR, HakeAM, QuaidKA, FarlowMR, GhettiB (2000) Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch Neurol57, 885–887.
6.
Pagnon de la VegaM, GiedraitisV, MichnoW, KilanderL, GünerG, ZielinskiM, LöwenmarkM, BrundinRM, DanforsT, IngelssonM (2021) The deletion causes early onset autosomal dominant Alzheimer’s disease by altering APP processing and increasing amyloid β fibril formation. Sci Transl Med13, eabc6184.
7.
SherringtonR, RogaevEI, LiangY, RogaevEA, LevesqueG, IkedaM, ChiH, LinC, LiG, HolmanK, TsudaT, MarL, FoncinJF, BruniAC, MontesiMP, SorbiS, RaineroI, PinessiL, NeeL, ChumakovI, PollenD, BrookesA, SanseauP, PolinskyRJ, WascoW, Da SilvaHA, HainesJL, Perkicak-VanceMA, TanziRE, RosesAD, FraserPE, RommensJM, St George-HyslopPH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature375, 754–760.
8.
LarnerAJ, DoranM (2006) Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol253, 139–158.
RogaevEI, SherringtonR, RogaevaEA, LevesqueG, IkedaM, LiangY, ChiH, LinC, HolmanK, TsudaT, MarL, SorbiS, NacimiasB, PiacentiniS, AmaducciL, ChumakovI, CohenD, LannfeltL, FraserPE, RommensJM, St George-HyslopPH (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease Type 3 gene. Nature376, 5–8.
11.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
12.
CraftS, TeriL, EdlandSD, KukullWA, SchellenbergG, McCormickWC, BowenJD, LarsonEB (1998) Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease. Neurology51, 149–153.
13.
MosconiL (2013) Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging1, 217–233.
SilvaDF, SelfridgeJE, LuJ, LE, RoyN, HutflesL, BurnsJM, MichaelisEK, YanS, CardosoSM, SwerdlowRH (2013) Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet22, 3931–3946.
17.
SwerdlowRH, KhanSM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses63, 8–20.
18.
SwerdlowRH, KhanSM (2009) The Alzheimer’s disease mitochondrial cascade hypothesis: An update. Exp Neurol218, 308–315.
19.
SwerdlowRH, BurnsJM, KhanSM (2014) The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta1842, 1219–1231.
20.
ManczakM, ParkBS, JungY, ReddyPH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromol Med5, 147–162.
21.
ManczakM, JungY, ParkBS, PartoviD, ReddyPH (2005) Time-course of mitochondrial gene expressions in mice brains: Implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem92, 494–504.
22.
ReddyPH, McWeeneyS, ParkBS, ManczakM, GutalaRV, PartoviD, JungY, YauV, SearlesR, MoriM, QuinnJ (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Upregulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet13, 1225–1240.
23.
ManczakM, ReddyPH (2012) Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum Mol Genet21, 5131–5146.
24.
SwierczyńskiJ, ScislowskiP, AleksandrowiczZ (1976) High activity of alpha-glycerophosphate oxidation by human placental mitochondria. Biochim Biophys Acta429, 46–54.
25.
DrouinJ (1980) Cloning of human mitochondrial DNA in Escherichia coli. J Mol Biol140, 15–34.
26.
HambletNS, RaglandB, AliM, ConyersB, CastoraFJ (2006) Mutations in mitochondrial-encoded cytochrome c oxidase subunits I, II, and III genes detected in Alzheimer’s disease using single-strand conformation polymorphism. Electrophoresis27, 398–408.
27.
CastoraFJ, ConyersB., MadricK, TrevinoM, Simsek-DuranF (2019) The T9861C mutation in the mtDNA-encoded cytochrome c oxidase subunit III gene occurs in high frequency but with unequal distribution in the AD brain. J Alzheimers Dis72, 257–269.
28.
PfafflMW, (2001) A new mathematical model for relative quantification in real-time RT–PCR. Nucl Acids Res29, 2002–2007.
29.
LivakKJ, SchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods25, 402–408.
30.
ColemanRA, DurmazC, WeechA, CastoraFJ (2016) Building a testable mathematical model for Alzheimer’s Disease using gene expression changes and biochemical systems theory (BST). Alzheimers Dement12, P440–P441.
31.
ColemanRA, SheltonM, ShiraliS, CastoraFJ, (2018) A mathematical model of Alzheimer’s disease simulates different gene therapy treatments and their effects on mitochondrial activity. Alzheimers Dement13, P366.
32.
SheltonM, CastoraFJ, KernsKA, ColemanRA (2020) Modeling the effects of respirasome supercomplex formation on AD progression by incorporation of mitochondrial gene expression data. Alzheimers Dement16, S2.
33.
SheltonMG, KernsKA, CastoraFJ, ColemanRA (2022) Incorporating mitochondrial gene expression changes within a testable mathematical model for Alzheimer’s disease: Stress response modulation predicts potential therapeutic targets. J Alzheimers Dis90, 109–117.
34.
PengY, ZhangH-W, CaoW-H, MaoY, ChengR-C (2020) Exploration of the potential biomarkers of papillary thyroid cancer (PTC) based on RT2 profiler PCR arrays and bioinformatics analysis. Cancer Manage Res12, 9235–9246.
35.
HooperC, MeimaridouE, TavassoliM, MelinoG, LovestoneS, KillickaR (2007) p53 is upregulated in Alzheimer’s disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett418, 34–37.
36.
WangX, SuB, LeeH-g, LiX, PerryG, SmithMA, ZhuX (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci29, 9090–9103.
37.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
38.
Luna-MuñozJ, Chávez-MacíasL, García-SierraF, MenaR (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis12, 365–375.
39.
BaigS, PalmerLE, OwenMJ, WilliamsJ, KehoePG, LoveS (2012) Clusterin mRNA and protein in Alzheimer’s disease. J Alzheimers Dis28, 337–344.
40.
MichishitaE, ParkYK, BurneskisJM, BarrettJC, HorikawaI (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell16, 4623–4635.
41.
OnyangoPI, CelicJM, McCafferyJD, Feinberg BoekeAP, (2002) SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A99, 13653–13658.
42.
SchlickerC, GertzM, PapatheodorouP, KachholzB, BeckerCFW, SteegbornC (2008) Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol382, 790–801.
43.
DikalovaAE, ItaniHA, NazarewiczRR, McMasterWG, FlynnCR, UzhachenkoR, FesselJP, GamboaJL, HarrisonDG, DikalovSI (2017) Sirt3 impairment and SOD2 hyperacetylation in vascular oxidative stress and hypertension. Circ Res121, 564–574.
44.
LinZ-F, XuH-B, WangJ-Y, LinQ, RuanZ, LiuF-B, JinW, HuangH-H, ChenX (2013) SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun441, 191–195.
45.
YanagisawaS, BakerJR, VuppusettyC, KogaT, ColleyT, FenwickP, DonnellyLE, BarnesPJ, ItoK (2018) The dynamic shuttling of SIRT1 between cytoplasm and nuclei in bronchial epithelial cells by single and repeated cigarette smoke exposure. PLoS One13, e0193921.
46.
DonmezG, WangD, CohenDE, GuarenteL (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell23, 320–332.
47.
BudihardjoI, OliverH, LutterM, LuoW, WangX (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol15, 269–290.
48.
IhenachoUK, MeachamKA, HarwigMC, WidlanskyME, HillRB (2021) Mitochondrial fission protein 1: Emerging roles in organellar form and function in health and disease. Front Endocrinol12, 660095.
49.
FiladiR, PendinD, PizzoP (2018) Mitofusin 2: From functions to disease. Cell Death Dis9, 330.
50.
GuoMY, ShangL, HuYY, JiangLP, WanYY, ZhouQQ, ZhangK, LiaoHF, YiJL, HanXJ (2018) The role of Cdk5-mediated Drp1 phosphorylation in A1-42 induced mitochondrial fission and neuronal apoptosis. J Cell Biochem119, 4815–4825.
51.
GilkersonR, De La Torre P, St VallierS (2021) Mitochondrial OMA1 and OPA1 as gatekeepers of organellar structure/function and cellular stress response. Front Cell Develop Biol9, 626117.
52.
FerozW, SheikhAMA (2020) Exploring the multiple roles of guardian of the genome: P53. Egypt J Med Hum Genet21, 49.
53.
DanialNN, KorsmeyerSJ (2004) Cell death: Critical control points. Cell116, 205–219.
54.
ObulesuM, LakshmiMJ (2014) Apoptosis in Alzheimer’s disease: An understanding of the physiology, pathology and therapeutic avenues. Neurochem Res39, 2301–2312.
55.
ChinnaduraiG, VijayalingamS, GibsonS (2008) BNIP3 subfamily BH3-only proteins: Mitochondrial stress sensors in normal and pathological functions. Oncogene27, S114–S127.
56.
WangT, ZhaoH, GaoH, ZhuC, XuY, BaiL, LiuJ, YanF (2018) Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line. Exp Ther Med15, 3197–3202.
57.
ShuklaS, RizviF, RaisuddinS, KakkarP (2014) FoxO proteins’ nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells. Free Rad Biol Med76, 185–199.
58.
WienerHW, PerryRT, ChenZ, HarrellLE, GoRCP (2007) A polymorphism in SOD2 is associated with development of Alzheimer’s disease. Genes Brain Behav6, 770–775.
59.
CieślikM, CzapskiGA, WójtowiczS, WieczorekI, WencelPL, StrosznajderRP, JaberV, LukiwWJ, StrosznajderJB (2020) Alterations of transcription of genes coding anti-oxidative and mitochondria-related proteins in amyloid β toxicity: Relevance to Alzheimer’s disease. Mol Neurobiol57, 1374–1388.
60.
MassaadCA, WashingtonTM, PautlerRG, KlannE (2009) Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A106, 13576–13581.
61.
SheppardKE, McArthurGA (2013) The cell-cycle regulator CDK4: An emerging therapeutic target in melanoma. Clin Cancer Res19, 5320–5328.
62.
EsterasN, BartoloméF, AlquézarC, AntequeraD, MuñozU, CarroE, Martín-RequeroA (2012) Altered cell cycle-related gene expression in brain and lymphocytes from a transgenic mouse model of Alzheimer’s disease [amyloid precursor protein/presenilin 1 (PS1)]. Eur J Neurosci36, 2609–2618.
63.
MohC, KubiakJZ, BajicVP, ZhuX, SmithMA, LeeH (2011) Cell cycle deregulation in the neurons of Alzheimer’s disease. Results Probl Cell Differ53, 565–576.
64.
Fernandez-MarcosPJ, AuwerxJ (2011) Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr93, 884S–890S.
65.
LeBleuVS, O’ConnellJT, HerreraKNG, Wikman-KocherH, PantelK, HaigisMC, de CarvalhoFM, DamascenaA, ChinenLTD, RochaRM, AsaraJM, Kalluri1R (2014) PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis. Nat Cell Biol16, 992–1015.
ZhuX, PerryG, SmithMA, WangX (2013) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis33(Suppl 1), S253–262.
70.
MalkaF, GuilleryO, Cifuentes-DiazC, GuillouE, BelenguerP, LombèsA, RojoM (2005) Separate fusion of outer and inner mitochondrial membranes. EMBO Rep6, 853–859.
71.
SongZ, GhochaniM, McCafferyJM, FreyTG, ChanDC (2009) Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell20, 3525–3532.
72.
LosónOC, SongZ, ChenH, ChanDC (2013) Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol Biol Cell24, 659–667.
73.
YuR, JinS-B, LendahlU, NistérM, ZhaoJ (2019) Human Fis1 regulates mitochondrial dynamics through inhibition of the fusion machinery. EMBO J38, e99748.
74.
NakamuraY, KitamuraN, ShinogiD, YoshidaM, GodaO, MuraiR, KaminoH, ArakawaH, (2012) BNIP3 and NIX mediate Mieap-induced accumulation of lysosomal proteins within mitochondria. PLoS One7, e30767.
75.
Ułamek-KoziołM, KockiJ, Bogucka-KockaA, PetniakA, Gil-KulikP, JanuszewskiS, BoguckiJ, JabłońskiM, Furmaga-JabłońkaW, BrzozowskaJ, CzuczwarSJ, PlutaR (2016) Dysregulation of autophagy, mitophagy, and apoptotic genes in the medial temporal lobe cortex in an ischemic model of Alzheimer’s disease. J Alzheimers Dis54, 113–121.
